OmniAb, Inc.
OABIHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeOmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United. The company carries a $307.3M market cap, placing it firmly in the small-cap category. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Market Cap
$307.3M
Beta
1.17
P/E (TTM)
—
P/E (Fwd)
-6.57
EPS (TTM)
$-0.48
EPS (Fwd)
$-0.32
ROE
-20.3%
ROA
-11.3%
Cash
$49.1M
Total Debt
$19.7M
Free CF
-$2.6M
52W Change
8.7%
Annual Financials
Cash vs Debt
With $49.1M in cash and $19.7M in debt, OABI maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$2.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -20.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $59.1M (2022) to $18.7M (2025), a 68% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence OmniAb, Inc.'s trajectory.